The following analysis is based on  data from the  Surveillance, Epidemiology, and End Results (SEER) Program ( SEER*Stat Database: Incidence - SEER 9 Regs Public-Use, Nov 2004 Sub (1973-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission.

Cancer proceeds through two phases, compensated, when the tumor does not cause any damage or distress, and de-compensated, when the patient suffers.  The following analysis implements the  conclusions of the previous epidemiological studies:

1. Breast cancer survival curves indicate that that the organism depends on the tumor. Tumor ablation in  compensated  cancers  is followed by a rising hazard rate .. In de-compensated or metastatic cancers the patient suffers mainly from the damage caused by the tumor   which is generally alleviated with  chemotherapy.
2. This phenomenon is observed also in other cancers   where it  is more pronounced in compensated cancers and  less in de-compensated cancers
3. The third analysis demonstrated that in advanced age cancer progression is slower  than in young patients

The graphs below depict age adjusted incidence and mortality of breast cancer in the period of 1973 -2002

For years,  age adjusted breast cancer incidence was relatively low and started rising during the last three decades. It might appear as if breast cancer became more aggressive.  However  since  age adjusted mortality actually declined  this conclusion  is wrong.  The rising incidence was driven  by new means to detect cancer like  mammography. Since breast cancer was detected earlier, and mortality did not rise, patients lived longer.  The rising incidence  does not indicate a change in cancer biology and this phenomenon is  known as lead time bias.  

The figure below on the left depicts age adjusted incidence of in situ carcinoma. Its rise indicates that more and more compensated cancers were detected. The right figure depicts age adjusted rates of distant cancer. While the age adjusted incidence remained virtually constant, mortality declined which is attributed to an improvement in chemotherapy.

Since patients lived longer with their cancer  its prevalence rose as well. The scheme below depicts the relationship between the two rates in a population.  When incidence exceeds mortality prevalence rises and vice versa.

The distance between the two curves is proportional to prevalence, and the above difference curve indicates that breast cancer prevalence rose.  In  male lung cancer patients this pattern is different. Initially both rates rose and from 1990 they declined.  This pattern is attributed to smoking habits. The decline  started when many males quit smoking.

Pancreatic cancer is   extremely aggressive as evident from the  short distance between the two curves.  

The distance between the adjusted incidence and mortality indicates cancer aggression. The narrower the distance the more aggressive the cancer.   

It is striking that age adjusted mortality of most chronic cancers declines. Like  the breast cancer mortality presented above.   The decline might  indicate that treatment became more effective. Particularly in de-compensated cancers. However this decline results from yet another epidemiological bias.  In advanced age patients suffer  from more than one disease. A patient dying from a stroke may carry into his grave an undetected cancer.   A rising stroke mortality might therefore be accompanied by a declining cancer  death rate. The curves below depict age specific mortality  rates of white residents in Connecticut  in the year 1998. (

The right curve depicts cancer death rate as percentage of all deaths (100*cancer/ all causes). The initial peak indicates that childhood cancers are the main cause of childhood mortality.  From the age of 15y the curve rises reaching a maximum at the age of  50y whereupon it declines. With advancing age cancer under-diagnosis bias rises which explains the observed declining cancer rate.

There is yet another factor which might contribute to the decline of cancer death rate.  In advanced age cancer progression is slower. Its prevalence rises and the age adjusted death rate declines.

Back to New Medicine